BACKGROUND: The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab significantly reduced major vascular events in patients with stable atherosclerotic cardiovascular disease, including patients with prior myocardial infarction (MI). Within the broad group of patients with prior MI, we hypothesized that readily ascertainable features would identify subsets who derive greater clinical risk reduction with evolocumab.
L
owering low-density lipoprotein cholesterol (LDL-C) has been an integral part of the treatment of patients with myocardial infarction (MI), with statins being the mainstay of therapy. 1 Recently, the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) showed that the PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab, when added to statin therapy, lowered LDL-C by 59% and significantly reduced the risk of cardiovascular events in patients with stable atherosclerotic cardiovascular disease, the majority of whom had a history of MI. 2 These data led the US Food and Drug Administration to issue a new indication in December 2017 for evolocumab to reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular disease and for the incorporation of evolocumab into guideline recommendations for patients with atherosclerotic cardiovascular disease, including prior MI. 3, 4 In accord with a growing desire for personalized and cost-efficient medicine, 5 it is reasonable to seek to identify subgroups of patients who benefit the most from potential therapies. To that end, we have previously shown that within the broad group of patients with a history of MI, several readily ascertainable features of the coronary artery disease history identified patients at high risk who derived greater relative and/or absolute risk reduction from therapies. In those other studies, those features were the timing from the most recent MI, the number of prior MIs, and the presence of residual multivessel coronary artery disease. [6] [7] [8] [9] We tested the efficacy of evolocumab in these 3 subgroups in the FOURIER trial.
METHODS

Study Population
FOURIER was a randomized, double-blind, placebo-controlled trial that enrolled 27 564 patients 40 to 85 years of age with clinically evident atherosclerotic cardiovascular disease (prior MI, prior nonhemorrhagic stroke, or symptomatic peripheral arterial disease) and additional risk factors placing them at increased cardiovascular risk, as previously described. 2, 10 Patients were required to have an LDL-C ≥70 mg/dL or non-high-density lipoprotein cholesterol ≥100 mg/dL during screening while taking an optimized lipid-lowering regimen (at least atorvastatin 20 mg daily or its equivalent, with or without ezetimibe). Relevant exclusions were recent MI or stroke within 4 weeks, planned or expected cardiac surgery or revascularization within 3 months after randomization, New York Heart Association class III or IV heart failure, or left ventricular ejection fraction <0.30. Full inclusion and exclusion criteria have been published previously. 10 The number of prior MIs and date of a patient's most recent MI were recorded, as was the presence of residual multivessel coronary artery disease, defined as ≥40% stenosis in ≥2 large vessels. The protocol was approved by ethics committees at each center, and all patients provided written informed consent. Patients were randomized 1:1 to receive subcutaneous evolocumab (either 140 mg every 2 weeks or 420 mg monthly, per patient preference) or matching placebo injection and were followed up for a median of 2.2 years (interquartile range, 1.8-2.5 years). The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. However, we encourage parties interested in collaboration and data sharing to contact the corresponding author directly for further discussions.
Outcomes
The primary end point of FOURIER was the composite of cardiovascular death, MI, stroke, coronary revascularization, or hospitalization for unstable angina; the key secondary end point was the composite of cardiovascular death, MI, or stroke. A central clinical events committee led by the TIMI Study Group (Thrombolysis in Myocardial Infarction), whose members were unaware of treatment assignment and lipid levels, adjudicated all efficacy end points. Definitions of the end points have been published previously.
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Statistical Analyses
As part of a prespecified analysis, patients were stratified on the basis of the number of prior MIs, the timing of prior MIs, and the extent of coronary disease. Baseline characteristics of the subgroups were compared by use of Kruskal-Wallis tests and χ 2 tests for continuous and categorical data, respectively.
Clinical Perspective
What Is New?
• We tested whether common and readily ascertainable features would identify subsets of patients who derive greater clinical risk reduction with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab.
• Patients with a more recent myocardial infarction (MI; within the past 2 years), multiple prior MIs, and residual multivessel coronary disease were at significantly higher risk of cardiovascular outcomes.
• The relative and absolute risk reductions in cardiovascular outcomes with evolocumab tended to be greater in these high-risk subgroups, with correspondingly lower numbers needed to treat.
What Are the Clinical Implications?
• Patients with a recent MI, those who have had multiple prior MIs, or those who have residual multivessel coronary artery disease are at high risk for major vascular events and experienced substantial relative and absolute risk reductions with low-density lipoprotein cholesterol lowering with evolocumab.
• Among patients with a history of MI, it would be reasonable to preferentially target PCSK9 inhibition to these high-risk patients.
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All efficacy analyses of evolocumab versus placebo were conducted on an intention-to-treat basis. Kaplan-Meier event rates were calculated through 3 years, and P values for timeto-event analyses are from log-rank tests. , high-intensity statin use, and LDL-C at baseline. HRs and 95% confidence intervals (CIs) for the effect of evolocumab versus placebo were generated with a Cox proportional hazards model without adjustment given the randomized comparison. Effect modification by subgroup on the efficacy of evolocumab was tested by incorporating interaction terms into the Cox models. Schoenfeld residuals were assessed in the Cox models, and the proportional hazards assumptions were not violated. Negative binomial regression analysis was performed to compare the total number of primary and key secondary end points between patients in the evolocumab and placebo groups. This model included an exposure variable for duration of follow-up because this could vary by subject. Incidence rate ratio and corresponding 95% CIs are reported from the negative binomial regression model. All analyses were conducted with Stata/IC version 14.2 (StataCorp LP, College Station, TX) or SAS version 9.4 (SAS Institute, Cary, NC). Values of P<0.05 were considered significant.
RESULTS
Study Population
A total of 22 351 patients (81% of overall trial) had a history of prior MI and constituted the study population for these analyses. The baseline characteristics of these patients and those of the overall trial are shown in Table  I 
Subgroups and Risk of Cardiovascular Outcomes
A total of 8402 patients (38%) had their qualifying MI within 2 years of randomization. Their median time from that MI was 0.6 years (interquartile range, 0.3-1.2 years). In contrast, in patients with an MI >2 years before randomization, the median time was 6 years (interquartile range, 3.7-11.0 years). The baseline characteristics of patients whose MI was recent versus remote are shown in Table 2 and Table II in the online-only Data Supplement).
After adjustment for baseline characteristics that were imbalanced between those with and without a high-risk feature, the high-risk features were still independent predictors of cardiovascular outcomes (Table 2). Furthermore, in a multivariable-adjusted model that simultaneously included all 3 high-risk features and the other baseline covariates, more recent MI, multiple prior MIs, and residual multivessel coronary disease remained independent predictors of the cardiovascular outcomes, with adjusted HRs for the primary end point of 1.37 (95% CI, 1.22-1.53), 1.78 (95% CI, 1.59-1.99), and 1.39 (95% CI, 1.24-1.56) and for the key secondary end point of 1.36 (95% CI, 1.18-1.57), 1.90 (95% CI, 1.65-2.19), and 1.34 (95% CI, 1.16-1.55), respectively (all P<0.001; see Table III in the online-only Data Supplement for details of the full model).
Subgroups and Benefit of LDL-C Lowering With Evolocumab
Evolocumab consistently lowered LDL-C by 59% to 61% regardless of time from most recent MI, number of prior MIs, or presence of residual multivessel coronary artery disease, with median achieved LDL-C in the evolocumab arm of 29 to 30 mg/dL ( Figures 1, 2C , and 3C). Given both the higher baseline risk and the tendency toward greater relative risk reductions in patients with high-risk features, the absolute risk reductions tended to be greater in those with high-risk features. For the primary and key secondary end points, they were as follows: 3.4% versus 0.8% and 2.9% versus 1.0%, respectively, for those within 2 years of versus ≥2 years from their qualifying MI; 3.7% versus 1.3% and 2.6% versus 1.7%, respectively, for those with multiple prior MIs versus only 1 prior MI; and 3.6% versus 1.2% and 3.4% versus 1.3%, respectively, for those with residual multivessel coronary artery disease versus those without (Figures 1 through 3) . The absolute risk reductions of the primary end point in the high-risk subgroups translated into a number needed to treat over 3 years of 27 to 30 compared with 54 in the entire subgroup of patients with MI. Furthermore, the cumulative incidence curves appeared to diverge after only ≈6 months in the higher-risk subgroups versus after at least 12 months in the lower-risk subgroups (Figures 2 and 3) .
Combining Subgroups
A total of 13 973 patients (63% of the MI subpopulation) had at least 1 high-risk feature. Baseline character- 
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istics comparing patients with any high-risk feature and those with no high-risk features are shown in Table V Figure 4) . P values for interactions between treatment and subgroups were 0.015 and 0.11, respectively. The absolute risk reductions with evolocumab for the primary and key secondary end points in patients with any high-risk feature were 3.0% (95% CI, 1.3-4.6) and 2.5% (95% CI, 1.1-3.9), respectively. In contrast, the corresponding values were −0.6% (95% CI, −3.0 to 1.8) and 0.5% (95% CI, −1.7 to 2.7) in patients with no high-risk features. Whereas the cumulative incidence curves appeared to diverge after only ≈6 months in the high-risk subgroup, the event curves started to appear to diverge only after 2 years in the low-risk group.
In a landmark analysis of patients with at least 1 highrisk feature, the reduction in cardiovascular death, MI, or stroke was 19% in the first year (HR, 0.81; 95% CI, 0.68-0.95) and 27% beyond the first year (HR, 0.73; 95% CI, 0.62-0.86; Figure I in the online-only Data Supplement). In terms of total events (first and recurrent), there were 1371 total primary end point events in the evolocumab arm and 1776 in the placebo arm, giving an incidence rate ratio of 0.80 (95% CI, 0.71-0.89; P<0.001). Likewise, there were 583 total key secondary end point events in the evolocumab arm and 779 in the placebo arm, giving an incidence rate ratio of 0.77 (95% CI, 0.67-0.88; P<0.001). Correspondingly, whereas the number of first primary end point events prevented for every 1000 patients treated for 3 years was 29, the number of total events prevented was 75.
DISCUSSION
We found that among patients with prior MI, those with a more recent MI, multiple prior MIs, or residual multivessel coronary artery disease were at higher risk of cardiovascular events and tended to experience greater and earlier cardiovascular risk reduction from LDL-C lowering with evolocumab. Conversely, patients who had had only 1 prior MI in the more distant past and no residual multivessel coronary artery disease were at lower risk, with no significant benefit from LDL-C lowering with evolocumab, at least over the time frame studied, with divergence of the event curves starting to appear only after 2 years.
The 3 high-risk features are based on their predictive ability in prior studies of patients with MI. [6] [7] [8] [9] 11, 12 Our findings in FOURIER validate the ability of these 3 readily ascertainable factors to predict risk. The greater absolute risk reductions observed with LDL-C lowering with evolocumab in these subgroups are thus, in part, a consequence of the higher baseline risk in these patients. Greater absolute risk reductions translate into lower numbers needed to treat. In this case, Analyses were performed in placebo arm only. Covariates in the model include age, sex, self-reported race, weight, region, history of stroke, peripheral artery disease, hypertension, diabetes mellitus, current smoking, estimated glomerular filtration rate <60 mL·min
, high-intensity statin use, and low-density lipoprotein cholesterol at baseline. CAD indicates coronary artery disease; CI, confidence interval; HR, hazard ratio; HR adj , adjusted HR; and MI, myocardial infarction. % indicates Kaplan-Meier 3-year event rate.
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to prevent 1 primary end point over 3 years, the number needed to treat was 27 to 30 in each of the highrisk groups versus 54 in the overall group of patients with prior MI and 79 to 130 in the low-risk subgroups. Such findings have implications for helping to define the patient populations who could benefit most from treatment and could be used to inform cost-effectiveness analyses. [13] [14] [15] There also tended to be greater relative risk reductions in cardiovascular outcomes with evolocumab in these high-risk subgroups. Such an observation suggests that these factors are identifying patients whose pathobiology is more quickly and significantly modifiable in response to LDL-C lowering. Indeed, we know from intracoronary vascular ultrasound studies that LDL-C lowering with evolocumab causes coronary plaque regression. 16 Furthermore, it has been shown with both statins and evolocumab that coronary plaque regression is greater in patients with greater baseline atheroma burden. 16, 17 It thus stands to reason that patients with the greatest burden of coronary atherosclerosis have the greatest potential for clinical benefit from aggressive LDL-C lowering. Complementing the findings using clinical variables, we and others have also demonstrated a similar pattern using genetic variants associated with coronary disease. 18, 19 Patients with minimal coronary atherosclerosis should still benefit from LDL-C lowering in terms of preventing plaque development, as has been shown in statin primary prevention trials.
1 However, such benefits would likely take more years to clearly manifest clinically than patients were followed up in FOURIER.
In terms of potential limitations, it should be noted that the details on prior MIs were based on medical history rather than review of laboratory data and electrocardiographic tracings; however, our approach is typical for large, global cardiovascular outcomes trials. In addition, the protocol did not mandate dedicated imaging of the extent of residual coronary artery disease in all patients but again relied on medical history. The cut point of at least a 40% stenosis is arbitrary. However, we do not think the specific degree of stenosis is important because the issue is not a hemodynamic one. Rather, we think the key point is the presence of appreciable coronary artery disease in >1 vessel. These data suggest that, going forward, for both clinical trials and clinical practice, assessment of the burden of coronary artery disease either clinically or through imaging may be useful for identifying high-risk patients emerge in lower-risk patients with a history of MI. Longer-duration trials of proprotein convertase subtilisinkexin type 9 inhibition are needed to explore this issue.
CONCLUSIONS
Patients with a history of MI who are closer to their most recent event, have had multiple prior MIs, or have residual multivessel coronary artery disease are at high risk for major vascular events and experienced substantial relative and absolute risk reductions with LDL-C lowering with evolocumab. With a goal of personalized medicine, among patients with a history of MI, it would be reasonable to preferentially target therapy to these high-risk patients. Cumulative incidence curves for the primary (A) and key secondary end point (B) by treatment arm in patients stratified into those with at least 1 high-risk feature (solid lines) or no high-risk features (dashed lines). P value for interaction between treatment and subgroup was 0.015 for the primary end point and 0.11 for the key secondary end point. CI indicates confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction; and RRR, relative risk reduction.
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